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1Background—Age-adjusted coronary artery disease (CAD) burden identified on coronary computed tomography angiography 
predicts major adverse cardiovascular event (MACE) risk; however, it seldom contributes to clinical decision making 
because of a lack of nomographic data. We aimed to develop clinically pragmatic age- and sex-specific nomograms of 
CAD burden using coronary computed tomography angiography and to validate their prognostic use.
Methods and Results—Patients prospectively enrolled in phase I of the CONFIRM registry (Coronary CT Angiography 
Evaluation for Clinical Outcomes) were included (derivation cohort: n=21,132; 46% female) to develop CAD nomograms 
based on age–sex percentiles of segment involvement score (SIS) at each year of life (40–79 years). The relationship 
between SIS age–sex percentiles (SIS%) and MACE (all-cause death, myocardial infarction, unstable angina, and late 
revascularization) was tested in a nonoverlapping validation cohort (phase II, CONFIRM registry; n=3030, 44% female) 
by stratifying patients into 3 SIS% groups (≤50th, 51–75th, and >75th) and comparing annualized MACE rates and time 
to MACE using multivariable Cox proportional hazards models adjusting for Framingham risk and chest pain typicality. 
Age–sex percentiles were well fitted to second-order polynomial curves (men: R2=0.86±0.12; women: R2=0.86±0.14). 
Using the nomograms, there were 1576, 965, and 489 patients, respectively, in the ≤50th, 51–75th, and >75th SIS% 
groups. Annualized event rates were higher among patients with greater CAD burden (2.1% [95% confidence interval: 
1.7%–2.7%], 3.9% [95% confidence interval: 3.0%–5.1%], and 7.2% [95% confidence interval: 5.4%–9.6%] in ≤50th, 
51–75th, and >75th SIS% groups, respectively; P<0.001). Adjusted MACE risk was significantly increased among 
patients in SIS% groups above the median compared with patients below the median (hazard ratio [95% confidence 
interval]: 1.9 [1.3–2.8] for 51–75th SIS% group and 3.4 [2.3–5.0] for >75th SIS% group; P<0.01 for both).
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2  Naoum et al  Age- and Sex-Specific Nomograms for Coronary Artery Disease Burden 
Coronary heart disease (CHD) remains to be a leading cause of morbidity and mortality in developed countries.1 
Its prevalence increases with age, which is a significant driver 
of absolute CHD event risk irrespective of coexisting conven-
tional cardiac risk factors.2 Although age is important for abso-
lute risk stratification, measures of coronary atherosclerotic 
burden that are adjusted for age and sex such as that provided 
by quantified coronary artery calcium scoring (CACS) are 
predictive of increased relative risk of CHD-related events.3,4
See Editorial by Raggi and Alexopoulos 
See Clinical Perspective
Coronary computed tomography angiography (CCTA) 
also has proven utility in the prediction of future CHD events 
beyond traditional risk factor assessment and across a range of 
age groups and patient populations.5–8 Unlike CACS, the focus 
with CCTA has been on identifying obstructive coronary artery 
disease (CAD) not only as a marker of risk but also because of its 
association with myocardial ischemia, symptoms, and as an indi-
cator for the potential need for invasive angiographic assessment. 
Quantifying the overall atherosclerotic disease burden may also 
be important; however, with a recent study showing that plaque 
extent quantified by CCTA provides additive risk prediction for 
cardiac events in a model integrating both clinical risk assess-
ment and the presence and severity of CAD.9 Moreover, there is 
growing evidence that the burden of nonobstructive CAD identi-
fied on CCTA10 or conventional angiography11 is also associated 
with increased risk of CHD events and mortality. A measure of 
global plaque burden from CCTA has been described: the seg-
ment involvement score (SIS) and has been shown to predict 
adverse outcomes.6 Despite this, the assessment of the overall 
burden of CAD often has minimal impact on clinical decision 
making because of lack of a clinically pragmatic tool for inte-
grating it into clinical practice. Nomographic data document-
ing the age- and sex-specific extent of CAD observed among 
patients presenting for CCTA present such a tool.
We accordingly performed a study with 3 aims; first, to 
develop age- and sex-specific nomograms of SIS percentiles 
(SIS%) using CCTA data in a derivation cohort; second, to 
assess the relationship between SIS% and major adverse car-
diovascular events (MACE); and third, to test the relationship 
between SIS% from the derivation cohort and observed events 
in a validation cohort.
Methods
Patient Population
Two study populations were identified from nonoverlapping phase I 
(derivation) and phase II (validation) cohorts of the CONFIRM reg-
istry (Coronary CT Angiography Evaluation for Clinical Outcomes: 
An International Multicenter). The rationale and methods of the 
CONFIRM registry have been previously described.12 Study approval 
from the local ethics committee or institutional review board was ob-
tained by the site principal investigator when required.
The present analysis involved 2 components: first, CCTA data 
from the derivation cohort were used to develop sex-specific nomo-
grams based on SIS (defined below) by age percentiles and analyzed 
in relation to MACE risk at medium-term follow-up (≈2 years); sec-
ond, the nomograms were validated by assessing observed MACE 
rates in the validation cohort based on SIS% assigned by cross-refer-
encing individual patient age, sex, and SIS values to the correspond-
ing percentile on the derived nomograms.
Derivation Cohort
Phase I of the CONFIRM trial prospectively enrolled 27 125 con-
secutive patients aged >18 years, and undergoing clinically indicated 
Conclusions—We have developed clinically pragmatic age- and sex-specific nomograms of CAD prevalence using coronary 
computed tomography angiography findings. Global plaque burden measured using SIS% is predictive of cardiac events 
independent of traditional risk assessment.
Clinical Trial Registration—URL: https://www.clinicaltrials.gov. Unique identifier: NCT01443637.   
(Circ Cardiovasc Imaging. 2017;10:e004896. DOI: 10.1161/CIRCIMAGING.116.004896.)
Key Words: computed tomography angiography ◼ coronary artery disease ◼ coronary angiography  
◼ epidemiology ◼ nomograms
Figure 1. Study flow chart demonstrating 
populations comprising the derivation and 
validation cohorts. CAD indicates coro-
nary artery disease; CONFIRM, Coronary 
CT Angiography Evaluation for Clinical 
Outcomes; and MACE, major adverse car-
diovascular event.
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CCTA between 2005 and 2009 in an observational registry per-
formed across 12 cluster sites in 6 countries (United States, Canada, 
Germany, Switzerland, Italy, and South Korea) with the primary aim 
of identifying CCTA characteristics predictive of death and MACE 
at medium-term follow-up. Patients enrolled in CONFIRM phase I 
without a known history of CAD (defined as prior myocardial infarc-
tion and revascularization) and aged between 40 and 79 years were 
included for the development of the CAD nomograms (patients aged 
<40 and ≥80 years were excluded because of relatively small num-
bers of patients in these age categories). The relationship between 
SIS% and outcomes was assessed in the subgroup of patients from 8 
of 12 sites that obtained MACE follow-up.
Validation Cohort
The Phase II CONFIRM registry cohort is a nonoverlapping popula-
tion of 4682 patients prospectively enrolled between 2005 and 2010 
with similar data collected to that in phase I, at 6 sites in 4 countries 
(United States, Canada, Austria, and South Korea). Patients in this 
cohort aged between 40 and 79 years with no history of prior CAD 
and with MACE follow-up were included.
Baseline Clinical Evaluation
In both phase I and II cohorts, patients underwent prospective clinical 
evaluation at the time of CCTA including identification of baseline 
demographic data, traditional cardiac risk factors, and assessment of 
chest symptom typicality for angina as previously defined.12
Coronary CT Angiography
CCTA was performed at all participating sites using a scan plat-
form with a minimum detector width of 64 slices according to ei-
ther local institutional policy or guidelines issued by the Society of 
Cardiovascular Computed Tomography.13,14 Image interpretation was 
performed at all sites by experienced observers with level III (or 
equivalent) accreditation and board certification in CCTA. Segmental 
analysis was performed using a 16-segment model of the coronary 
arteries. Coronary atherosclerosis was considered present in a seg-
ment if there were any tissue structures >1 mm2 located either within 
or adjacent to the coronary artery lumen that could be differentiated 
from surrounding pericardial tissue, epicardial fat, or the vessel lu-
men itself.12 To provide a clinically pragmatic nomographic tool, the 
Table 1. Clinical Characteristics of the Nomogram Derivation Cohort
Demographics
All Patients 10-Year Age Group
N=21 132*
40–49 y
N=4485
50–59 y
N=6755
60–69 y
N=6670
70–79 y
N=3222 P Value†
Age, y 58.5±9.8 45.1±2.8 54.6±2.9 64.3±2.8 73.7±2.8 <0.001 (<0.001)
Female sex, no. (%) 9714 (46) 1779 (40) 3009 (45) 3209 (48) 1717 (53) <0.001 (<0.001)
Body mass index, kg/m2 27.3±5.2 27.9±5.5 27.6±5.4 27.2±5.0 26.7±4.5 <0.001 (<0.001)
Cardiac risk factors
  Diabetes mellitus 3230 (15) 459 (10) 951 (14) 1221 (18) 599 (19) <0.001 (<0.001)
  Hypertension 10 581 (51) 1742 (39) 3180 (48) 3642 (55) 2017 (63) <0.001 (<0.001)
  Dyslipidemia 11 873 (57) 2004 (45) 3810 (57) 4104 (62) 1955 (61) <0.001 (<0.001)
  Current smoker 3671 (17) 1135 (25) 1263 (19) 945 (14) 328 (10) <0.001 (<0.001)
Chest pain typicality
  Typical angina 2755 (15) 585 (15) 832 (14) 837 (14) 501 (19) <0.001 (<0.001)
  Atypical angina 7272 (39) 1797 (45) 2440 (41) 2141 (37) 894 (33) <0.001 (<0.001)
  Noncardiac 2097 (11) 496 (12) 602 (10) 639 (11) 360 (13) <0.001 (0.22)
  Asymptomatic 6417 (35) 1157 (29) 2131 (35) 2177 (38) 952 (35) <0.001 (<0.001)
     Overall <0.001 (<0.001)
Framingham risk score
Risk score, mean±SD 13.4±9.8 7.2±4.6 11.9±6.8 16.6±9.7 18.8±14.1 <0.001 (<0.001)
Risk category, no. (%)
  <10% 9672 (46) 3592 (81) 3255 (49) 1725 (26) 1100 (34) <0.001 (<0.001)
  10%–20% 7386 (35) 735 (17) 2638 (40) 3043 (46) 970 (30) <0.001 (<0.001)
  >20% 3849 (18) 114 (3) 783 (12) 1822 (28) 1130 (35) <0.001 (<0.001)
     Overall <0.001 (<0.001)
Coronary artery disease
  Normal 8396 (40) 2815 (63) 3005 (44) 1998 (30) 578 (18) <0.001 (<0.001)
  Nonobstructive 7596 (36) 1113 (25) 2353 (35) 2731 (41) 1399 (43) <0.001 (<0.001)
  Obstructive (≥50%) 5140 (24) 557 (12) 1397 (21) 1941 (29) 1245 (39) <0.001 (<0.001)
     Overall <0.001 (<0.001)
*Body mass index (n=16 721); diabetes mellitus (n=21 014); hypertension (n=20 932); dyslipidemia (n=20 987); current smoker 
(n=20 984); chest pain typicality (n=18 541); Framingham risk score (n=20 907); otherwise complete.
†P values for analysis of variance or χ2 test (P value for χ2 test for trend or Cuzick’s test for trend in brackets).
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SIS, defined as the number of coronary segments with any athero-
sclerotic plaque irrespective of stenosis severity, was used to quan-
tify atherosclerotic burden (score between 0 and 16) for the purpose 
of developing the nomograms. In addition, the presence of obstruc-
tive disease was also assessed by visual assessment and is reported 
at baseline on a per-patient basis (≥50% luminal narrowing in any 
coronary segment), and incorporated into the stenosis severity score 
by summing the product of segmental involvement (0 or 1) by steno-
sis severity (0–3) for each of the 16 segments yielding a total score 
between 0 and 48.8
Outcomes
All patients in the CONFIRM registry were followed for all-cause 
death for ≥1 year. In US sites, death was determined from the national 
death index; and in non-US sites, death was determined by direct in-
terview, telephone contact with the patient’s family or primary care 
physician, or review of medical records. Additional events were as-
certained at some sites including myocardial infarction, unstable an-
gina, and late revascularization by direct patient interview, telephone 
contact, or review of medical record.
For the present analysis, the primary end point was MACE inclu-
sive of all-cause death, myocardial infarction, unstable angina, or late 
revascularization (defined as revascularization occurring >90 days 
from enrollment).
Statistical Analysis
Continuous variables are presented as mean± SD and categori-
cal variables as frequencies (%). Comparisons between 2 groups 
were performed using a χ2 test or Mann–Whitney test, and between 
multiple groups using a χ2 test and χ2 test for trend or 1-way analysis 
of variance and Cuzick’s test for trend, as appropriate.
Nomograms were developed from the derivation cohort by first 
plotting percentiles (10th, 20th, 30th, 40th, 50th, 60th, 70th, 80th, 
and 90th) of SIS values at each year of life for men and women. 
Polynomial curves (second order) were subsequently fitted to each 
percentile using GraphPad Prism (V6.0d; GraphPad Software, La 
Jolla, CA).
To assess the relationship between SIS% and MACE risk in the 
derivation cohort, patients were divided into 3 SIS% groups (≤50th, 
51–75th, and >75th) based on the distribution of observed SIS values 
within 10-year age groups (40–49, 50–59, 60–69, and 70–79 years) 
for both sexes separately using data from the overall derivation co-
hort. MACE risk was then analyzed in relation to SIS% group in the 
subgroup from sites with MACE follow-up using univariable Cox 
proportional hazards models with reporting of the hazard ratio and 
95% confidence interval.
The relationship between SIS% and MACE risk was then as-
sessed using the nomograms. In the validation cohort, each patient 
was individually assigned an SIS% value by cross-referencing pa-
tient age (by year of life), sex, and SIS value to the corresponding 
SIS% on the nomograms. Patients were then similarly divided into 
3 SIS% groups (≤50th, 51–75th, and >75th) using the individually 
assigned SIS%, and MACE risk was analyzed between SIS% groups 
using multivariable Cox proportional hazards models adjusting for 
Framingham risk score and chest pain typicality.
In both derivation and validation cohorts, time to MACE was 
analyzed according to SIS% group (≤50th, 51–75th, and >75th) 
using Kaplan–Meier survival curves with reporting of the log-
rank test P value. Patients who underwent early revasculariza-
tion (within 90 days of enrollment) were censored at the time 
Table 2. Age- and Sex-Related Differences in Coronary Artery Disease Prevalence and Characteristics
CAD Severity
Men
N=11 418
Women
N=9714
All 40–49 y 50–59 y 60–69 y 70–79 y All 40–49 y 50–59 y 60–69 y 70–79 y
N=11418 N=2706 N=3746 N=3461 N=1505 N=9714 N=1779 N=3009 N=3209 N=1717
Normal 3495 (31) 1491 (55) 1219 (33) 627 (18) 158 (10)* 4901 (50)† 1324 (74) 1786 (59) 1371 (43) 420 (24)*
Nonobstructive 4585 (40) 828 (31) 1557 (42) 1555 (45) 645 (43)* 3011 (31)† 285 (16) 796 (26) 1176 (37) 754 (44*
Obstructive (≥50%) 3338 (29) 387 (14) 970 (26) 1279 (37) 702 (47)* 1802 (19)† 170 (10) 427 (14) 662 (21) 543 (32)*
Segmental involvement
  Segment involvement score 2.6±2.8 1.2±2.0 2.3±2.7 3.4±2.9 4.2±3.0† 1.5±2.2† 0.6±1.3 1.1±1.8 1.8±2.3 2.7±2.6*
  Absolute segment involvement, no. (%)
   0 segment 3495 (31) 1491 (55) 1219 (33) 627 (18) 158 (11)* 4901 (50)† 1324 (74) 1786 (59) 1371 (43) 420 (24)*
   1 segment 1832 (16) 477 (18) 667 (18) 505 (15) 183 (12)* 1515 (16) 203 (11) 469 (16) 549 (17) 294 (17)*
   2 segments 1381 (12) 255 (9) 486 (13) 484 (14) 156 (10)‡ 1035 (11)† 113 (6) 287 (10) 391 (12) 244 (14)*
   3 segments 1174 (10) 166 (6) 377 (10) 441 (13) 190 (13)* 721 (7)† 61 (3) 178 (6) 282 (9) 200 (12)*
   4 segments 948 (8) 98 (4) 317 (9) 327 (9) 206 (14)* 475 (5)† 31 (2) 88 (3) 189 (6) 167 (10)*
   ≥5 segments 2588 (23) 219 (8) 680 (18) 1077 (31) 612 (41)* 1067 (11)† 47 (3) 201 (7) 427 (13) 392 (23)*
Plaque characteristics, segments per patient
  Calcified plaque 0.9±1.8 0.3±0.9 0.8±1.6 1.3±2.1 1.7±2.5* 0.6±1.3† 0.1±0.5 0.3±0.9 0.7±1.4 1.2±1.9*
  Noncalcified plaque 0.3±0.9 0.3±0.8 0.3±0.9 0.4±0.9 0.4±1.0* 0.2±0.7† 0.2±0.6 0.2±0.7 0.3±0.8 0.3±0.8*
  Mixed plaque 0.8±1.8 0.4±1.2 0.8±1.7 1.1±2.0 1.3±2.2* 0.4±1.2† 0.1±0.7 0.3±1.0 0.5±1.3 0.8±1.5*
Stenosis severity score 3.7±4.5 1.6±3.0 3.2±4.2 4.7±4.8 6.1±5.2* 2.0±3.3† 0.8±1.9 1.4±2.7 2.4±3.5 3.7±4.1*
Plus-minus values are mean±SD. CAD indicates coronary artery disease.
*P<0.001 for analysis of variance or χ2 test for comparison between 10-year age groups (and P<0.001 for χ2 test for trend or Cuzick’s test for trend).
†P<0.001 for unpaired comparison (χ2 test or Mann–Whitney test) between men and women.
‡P<0.001 for χ2 test for comparison between 10-year age groups and P=0.01 for χ2 test for trend.
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Figure 2. Coronary artery disease nomograms by age percentiles for males (A) and females (B).
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of revascularization (included as no event during follow-up to 
the time of their early revascularization) for the MACE survival 
analyses to avoid inclusion of potentially nonclinically driven 
revascularization that occurred immediately after obtaining CT coro-
nary angiography results.
Statistical analyses were performed using STATA statistical soft-
ware, version 13 (StataCorp, College Station, TX) and a 2-tailed P 
value <0.05 was considered statistically significant.
Results
Among the 27 125 patients enrolled in phase I of the CON-
FIRM registry, 21 132 patients met the above inclusion cri-
teria and comprised the nomogram derivation cohort. Of 
these, MACE follow-up was available in 13 735 patients, who 
comprised the nomogram outcome cohort. Among the 4682 
patients in phase II, 3030 patients met inclusion criteria for the 
validation cohort (Figure 1).
Nomogram Derivation Cohort
Baseline clinical characteristics of the nomogram deriva-
tion cohort are presented in Table 1 stratified by 10-year age 
groups. The prevalence of cardiovascular risk factors increased 
with age apart from smoking, which decreased. Age- and sex-
related differences in CAD prevalence and plaque characteris-
tics are reported in Table 2. As expected, global plaque burden 
quantified by SIS was higher overall in men compared with 
women (2.6±2.8 versus 1.5±2.2; P<0.001) and increased with 
age in both sexes.
There were 11 141 male and 9730 female subjects in 
the derivation cohorts for the CAD nomograms presented 
in Figure 2 with adequate numbers of patients represented 
at each year of life between 40 and 79 years (289±97 and 
243±80 patients per year of life for men and women, respec-
tively, Figure I in the Data Supplement).Coefficient and R2 
values for the second-order polynomial curves fitted to each 
age percentile (10th–90th) are presented in Table I in the 
Data Supplement and demonstrated in Figure II in the Data 
Supplement. The age cutoffs at which the median (50th) 
SIS% corresponded to the presence of CAD (SIS score ≥1) 
were 49 years for men and 65 years for women. SIS% values 
Figure 3. Annualized event rates in the derivation cohort stratified 
by segment involvement score (SIS%) groups, 10-year age group 
and sex.
Table 3. MACE Risk According to SIS% Value in the 
Derivation Cohort
 HR (95% CI) P Value
All (n=13 735)
  ≤50th percentile SIS% Reference …
  51–75th percentile SIS% 2.6 (2.1–3.3) <0.001
  >75th percentile SIS% 6.9 (5.7–8.4) <0.001
Males (n=7450)
  ≤50th percentile SIS% Reference …
  51–75th percentile SIS% 2.3 (1.8–3.0) <0.001
  >75th percentile SIS% 5.6 (4.4–7.2) <0.001
Females (n=6285)
  ≤50th percentile SIS% Reference …
  51–75th percentile SIS% 2.9 (1.9–4.3) <0.001
  >75th percentile SIS% 9.2 (6.6–12.8) <0.001
CI indicates confidence interval; HR, hazard ratio; MACE, major adverse 
cardiovascular event; and SIS, segment involvement score.
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increased more rapidly with ageing in women compared with 
men (Figure 2).
Relationship Between SIS% and MACE in the 
Derivation Cohort
Differences in baseline characteristics between patients from 
sites with MACE follow-up versus patients from sites without 
MACE follow-up are presented in Table II in the Data Supple-
ment. Cardiovascular risk factors and typical angina were less 
prevalent in patients with MACE follow-up.
Among the 13 375 patients in the nomogram outcome 
cohort, there were a total of 541 events (187 female; 354 male) 
at a mean follow-up of 2.4±1.2 years (138/541 all-cause death; 
173/541 myocardial infarction/unstable angina, and 230/541 
late revascularization). The annualized event rate was 1.8% 
(95% confidence interval [CI]: 1.6%–1.9%) and increased 
with age (40–49 years: 0.7% [95% CI: 0.6%–1.0%]; 50–59 
years: 1.3%; 60–69 years: 2.0% [95% CI: 1.8%–2.3%]; 70–
79 years: 4.6% [3.9%–5.3%]; P<0.001). Annualized MACE 
rates were increased in the higher SIS% groups (51st–75th 
and >75th) compared with patients in the ≤50th SIS% group 
within each 10-year age group; however, the highest event 
rates were observed in older patients (Figure 3).
Both men and women in the higher SIS% groups also had 
an increased relative MACE risk (Table 3; Figure 4). However, 
in younger women (<60 years), the presence of CAD burden 
above the median was not associated with an increase in rela-
tive MACE risk unless the degree of CAD burden was elevated 
>75th percentile (Table 4). Conversely, among younger men, 
the presence of any CAD burden above the median was associ-
ated with a markedly elevated relative MACE risk that appeared 
to diminish with older age, although remain significant.
Patients in higher SIS% groups also had an increased 
relative risk of all-cause death when this was analyzed sep-
arately in the entire derivation cohort (Table III in the Data 
Supplement).
Validation Cohort
After assigning SIS% to all patients in the validation cohort 
by cross-referencing with the derivation nomograms, there 
were 1576, 965, and 489 patients, respectively, in the ≤50th, 
51–75th, and >75th SIS% groups. Clinical and cardiac CT 
characteristics of the validation cohort are presented in Table 
IV in the Data Supplement. Overall, patients in the validation 
cohort had relatively higher overall cardiovascular risk with 
716 of 3030 (25%) of patients having a Framingham Risk 
Score >20%. Apart from diabetes mellitus, cardiovascular risk 
factors were more prevalent among patients in SIS% groups 
above the 50th percentile; however, the Framingham Risk 
Score did not correlate with SIS% group.
MACE occurred in 162 of 3030 patients (19/162 all-cause 
death; 69/162 myocardial infarction/unstable angina, and 74/162 
late revascularization) at a mean follow-up of 2.0±1.2 years 
yielding an annualized event rate of 3.3% (95% CI: 2.8%–3.9%). 
There was a significant correlation between SIS% group and 
the observed annualized event rates in the validation cohort 
(2.1% [95% CI: 1.7%–2.7%], 3.9% [95% CI: 3.0%–5.1%], 
and 7.2% [95% CI: 5.4%–9.6%] in ≤50th, 51–75th, and >75th 
SIS% groups, respectively; P<0.001). Differences in annualized 
event rates between SIS% groups (≤50th, 51–75th, and >75th) 
remained significant for myocardial infarction/unstable angina, 
and late revascularization but not death (Table 5). SIS% was pre-
dictive of annualized event rates in the validation cohort for each 
10-year age group (Figure 5). For both sexes, SIS% groups above 
the median had an elevated risk of MACE compared with patients 
below the median (Figure 6). After adjusting for Framingham 
risk and chest pain typicality, MACE remained significantly 
increased in patients with an SIS% above the median (Table 6).
Discussion
We have developed age- and sex-specific nomograms of CAD 
extent using CCTA findings from a large multicenter registry. 
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Figure 4. Kaplan–Meier curves demonstrating major adverse car-
diovascular event-free survival in the derivation cohort stratified 
by segment involvement score (SIS%) groups. P value for log-
rank test for comparison with ≤50th SIS% group.
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In doing so, we provide a clinically pragmatic approach for 
quantifying global plaque burden using CCTA on an individ-
ual patient level and relative to the disease burden observed in 
patients of the same age and sex referred for CCTA. Impor-
tantly, SIS% derived from the nomograms was shown to pre-
dict both annualized event rates and adjusted relative MACE 
risk in a nonoverlapping validation cohort. These findings 
emphasize the important prognostic use of estimating global 
plaque burden by age percentiles independent of traditional 
Framingham risk and without the need to incorporate infor-
mation regarding stenosis severity, CAD location, or plaque 
features.
Despite a prevailing clinical perception that CAD is ubiq-
uitous in older age and more common in men than women, 
the extent of CAD burden by year of life and differences in 
segmental involvement between men and women have been 
poorly documented. With the growing clinical adoption of 
coronary CTA for the evaluation of low-to-intermediate risk 
patients, nomographic data are becoming increasingly perti-
nent. Such data facilitate an understanding of CCTA findings 
on an individual patient level in the context of expected dis-
ease burden among patients of the same age and sex analo-
gous to the interpretation of CACS.15 As prior studies have 
described age- and sex-related trends in the prevalence of 
obstructive CAD, cardiovascular events, and the extent of 
coronary artery calcification,1,8,15 there are no studies report-
ing segmental disease burden stratified by age percentiles. 
Importantly, there are no such studies using CCTA, which 
is able to identify noncalcified plaque that is not captured 
by calcium scoring and is more sensitive for identifying 
nonobstructive plaque than both invasive angiography and 
coronary flow reserve testing.
An important component of our study was the ability 
to demonstrate a relationship between global plaque bur-
den quantified by SIS% using the nomograms and cardiac 
events in a validation cohort and independent of traditional 
Framingham risk. The incremental prognostic use of coro-
nary CCTA beyond traditional risk assessment is now well 
established across a range of patient populations including 
patients without any cardiac risk factors.16 These studies have 
focused largely on defining the value of CCTA through the 
identification of obstructive CAD, particularly proximal and 
multivessel disease, while looking at nonobstructive disease 
in a binary fashion. Moreover, recent CCTA studies have 
evaluated the ability of CCTA to predict events based on the 
presence of high-risk plaque features. In our study, we inten-
tionally used age-based segmental involvement to preserve 
the simplicity of the nomograms and found it was also pre-
dictive of events. Many studies have now established a clear 
relationship between CAD burden and outcomes irrespective 
of stenosis assessment.6 The prognostic use of CACS, a quan-
titative measure of overall calcific atherosclerotic burden, 
has been demonstrated in numerous studies although these 
have primarily evaluated asymptomatic patients (17–18). 
Similarly, CCTA studies have demonstrated prognostic util-
ity using scores that quantify CAD burden with and without 
stenosis weighting (stenosis severity score and SIS, respec-
tively).5 More recently, plaque extent using CCTA was shown 
to have incremental risk prediction for CHD events in a model 
that included clinical risk assessment and the presence and 
Table 4. MACE Risk According to SIS% Within 10-Year Age Groups and Stratified by Sex in the Derivation Cohort
40–49 y 50–59 y 60–69 y 70–79 y
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Males
  ≤50th percentile SIS% Reference … Reference … Reference … Reference …
  51–75th percentile SIS% 11.0 (3.2–37.9) <0.001 4.1 (2.2–7.4) <0.001 2.5 (1.5–4.0) <0.001 1.8 (1.1–3.0) 0.03
  >75th percentile SIS% 26.2 (7.7–89.2) <0.001 10.7 (6.0–19.2) <0.001 5.0 (3.4–7.4) <0.001 2.7 (1.7–4.2) <0.001
Females
  ≤50th percentile SIS% Reference … Reference … Reference … Reference …
  51–75th percentile SIS% 1.5 (0.2–12.1) 0.73 2.2 (1.0–5.0) 0.053 3.9 (2.0–7.5) <0.001 2.3 (1.1–4.9) 0.04
  >75th percentile SIS% 5.1 (1.4–18.1) 0.01 10.3 (5.2–20.2) <0.001 10.9 (6.3–18.9) <0.001 5.0 (2.7–9.2) <0.001
CI indicates confidence interval; HR, hazard ratio; MACE, major adverse cardiovascular event; and SIS, segment involvement score.
Table 5. Annualized Event Rates Stratified by SIS% Group in the Validation Cohort
Annualized Event Rate (95% CI)
P Value≤50th SIS% 51–75th SIS% >75th SIS%
MACE (combined end point) 2.1% (1.7%–2.7%) 3.9% (3.0%–5.1%) 7.2% (5.4%–9.6%) <0.001
Death 0.3% (0.1%–0.6%), 0.4% (0.2%–0.9%) 0.5% (0.2%–1.2%) 0.50
Myocardial infarction/UA 0.8% (0.6%–1.3%), 0.9% (0.6%–1.5%) 2.6% (1.8%–3.9%), <0.001
Late revascularization 1.1% (0.8%–1.5%), 2.3% (1.6%–3.2%) 3.7% (2.5%–5.6% <0.001
CI indicates confidence interval; MACE, major adverse cardiovascular event; SIS, segment involvement score; and UA, 
unstable angina.
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severity of CAD.9 Although there is no doubt that the extent 
and severity of obstructive disease and plaque features confer 
prognostic information, it seems that simple quantification of 
CAD segmental involvement alone also provides prognos-
tically useful information independent of traditional clini-
cal risk assessment. This may be because of an association 
between higher disease burden and an increased likelihood of 
coexisting luminal stenosis as was evident in our study (Table 
IV in the Data Supplement). Alternatively, the higher rates 
of CHD events may be related to an increased likelihood of 
developing vulnerable plaques that are capable of causing a 
cardiac event in patents with more atherosclerosis. Until now, 
however, there have been no clinically useful tools for under-
standing age- and sex-specific disease burden using CCTA on 
the individual patient level.
Apart from establishing nomographic data and establish-
ing its prognostic use, our data also emphasize the importance 
of age as a clinical risk factor for CHD events. Although 
SIS% was predictive of increased relative MACE risk at all 
age groups, the annualized event rates were more significantly 
increased in older patients (Figure 3), particularly among 
women. Age has been a long-established driver of absolute 
risk for CHD events. Indeed, age is significantly weighted in 
absolute risk models based on the presence and severity of 
conventional cardiac risk factors, such as the Framingham 
risk score.2,17 Patients in older age groups often have an 
increased risk independent of cardiovascular risk factors; and 
conversely, patients in younger age groups often do not reach 
treatment thresholds despite significant risk factors especially 
young women.18 This may be simply explained by the higher 
disease burden seen in older age19 (as shown in the nomo-
grams). Future applications of the nomogram as a risk tool 
for guiding clinical decision making in addition to risk factor 
assessment need to assess its performance relative to that of 
absolute SIS for disease burden quantification, analogous to 
the studies that have shown improved prediction of cardiac 
events using absolute CACS compared with age- and sex-
race/ethnicity percentiles.20
Limitations
First, our derivation cohort consisted of predominantly symp-
tomatic patients and our nomographic data therefore do not 
reflect normative CAD burden for the general population. 
However, CCTA is not routinely performed in the general 
population and normative data for patients in whom CCTA 
is clinically indicated remain important. In the present study, 
we did adjust for symptom typicality in the outcomes analysis 
in the validation cohort and importantly found that SIS per-
centiles were still predictive of MACE. Nevertheless, future 
Figure 5. Annualized event rates in the validation cohort based 
on segment involvement score (SIS%) groups assigned using the 
derived nomograms and stratified by 10-year age groups.
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Figure 6. Kaplan–Meier curves demonstrating major adverse car-
diovascular (MACE)-free survival in the validation cohort stratified 
by segment involvement score (SIS%) groups assigned using 
the derived nomograms. P value for log-rank test for comparison 
with ≤50th SIS% group.
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studies validating the use of the nomograms in an asymp-
tomatic population are needed to confirm the potential role 
of CCTA for cardiac risk stratification in a more general 
population, which have generally undergone such assessment 
using CACS. Second, the follow-up period was limited to the 
medium term (≈2 years). Although we would expect CAD 
burden to be more predictive of MACE in the long term, fur-
ther studies are needed to confirm this. Third, only sites that 
obtained MACE follow-up were included, which resulted in a 
substantial proportion of patients in the derivation cohort not 
being included in the outcomes analysis. Selection bias may 
have therefore affected the outcomes analysis in the derivation 
cohort; however, all-cause mortality, which was collected at 
all sites, was shown to still be predicted by SIS% in a sec-
ondary analysis (Table III in the Data Supplement). Moreover, 
in the second component of our study, SIS% was shown to 
be prognostically important in an unrelated validation cohort 
confirming their prognostic use. Fourth, although the nomo-
grams were predictive in the validation cohort, these patients 
were at higher risk and future studies should address the 
predictive value of our nomograms in different risk groups. 
Finally, we do not have data regarding downstream medical 
therapy, which was left to the discretion of the treating physi-
cian who was not blinded to the CCTA result. This treatment 
effect may have impacted subsequent events and future stud-
ies should address the impact of treatment modification based 
on global CAD burden on patient outcomes.
Conclusions
We have developed clinically pragmatic age- and sex-specific 
nomograms of CAD prevalence using CCTA findings for 
the first time that can be conveniently used to assess global 
CAD burden in an individual patient as it relates to all patients 
referred for CCTA. These findings provide for CCTA a mea-
surement analogous to the coronary calcium score used in 
noncontrast gated cardiac CT. Segmental plaque involvement 
by age–sex percentiles is predictive of MACE in a nonover-
lapping validation cohort, independent of traditional risk fac-
tor assessment, highlighting the prognostic importance of 
global plaque burden.
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CLINICAL PERSPECTIVE
Coronary computed tomography angiography has established itself as a robust test for the diagnosis and exclusion of ana-
tomic coronary artery disease with high sensitivity and overall accuracy as compared with invasive coronary angiography. 
Moreover, computed tomography coronary angiography provides important prognostic information including excellent 
prognosis in the absence of coronary artery disease and an elevated relative risk of major adverse cardiac events in the 
presence of nonobstructive disease and with increasing obstructive coronary artery disease severity and extent. Although 
atherosclerotic disease burden is a known predictor of major adverse cardiac event, it seldom affects clinical decision mak-
ing because of a lack of nomographic data. In the present study, we develop age- and sex-specific nomograms based on data 
from 21 132 patients referred for clinically indicated coronary computed tomography angiography across the globe. These 
clinically pragmatic charts allow the clinician to now have a better understanding of how the individual patient’s atheroscle-
rotic disease burden relates to other patients of similar age and sex referred for coronary computed tomography angiography. 
Importantly, our nomographic curves were shown to be predictive of major adverse cardiac event in a separate validation 
cohort. These data allow the clinician to have a deeper understanding therefore of not only their patients’ disease burden but 
also their risk, potentially facilitating more informed discussions around downstream risk modification.
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SUPPLEMENTAL	MATERIAL	
	
	
	
	
	
	
	
	 	
Supplementary	Table	1:	Coefficients	for	second-order	polynomial	fitted	curves*	used	in	age-SIS	
percentile	charts	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 	
	 	 Coefficients	 	 	
	 a	 b	 c	 R2	
Males		 	 	 	 	
				10th		 0.0014	 -0.1523	 3.9630	 0.60	
				20th		 0.0013	 -0.1052	 2.1140	 0.73	
				30th		 0.0010	 -0.0437	 -0.1301	 0.84	
				40th		 0.0006	 0.0436	 -3.0490	 0.90	
				50th		 -0.0008	 0.2136	 -7.4670	 0.96	
				60th		 -0.0012	 0.2788	 -9.2010	 0.91	
				70th		 -0.0027	 0.4620	 -13.9600	 0.95	
				80th		 -0.0035	 0.5684	 -16.2100	 0.94	
				90th		 -0.0042	 0.6570	 -17.2000	 0.92	
	 	 	 Mean	±	SD	 0.86±0.12	
	 	 	 	 	
Females	 		 		 		 		
				10th†	 –	 –	 –	 –	
				20th		 0.0013	 -0.1411	 3.7290	 0.53	
				30th		 0.0018	 -0.1885	 4.8140	 0.79	
				40th		 0.0026	 -0.2597	 6.4210	 0.88	
				50th		 0.0028	 -0.2513	 5.6480	 0.93	
				60th		 0.0021	 -0.1584	 2.7850	 0.93	
				70th		 0.0015	 -0.0517	 -0.5120	 0.94	
				80th		 0.0018	 -0.0794	 1.0630	 0.95	
				90th		 0.0009	 0.0462	 -1.7710	 0.93	
	 	 	 Mean	±	SD	 0.86±0.14	
*	Polynomial	fitted	curves	for:	SIS	=	a	×	(age)2	+	b	×	(age)	+	c.	
†Curve	not	fitted	due	to	SIS	value	of	0	at	percentile	10	for	all	females	
between	40	and	79yrs.	
Supplementary	Table	2:	Differences	in	baseline	characteristics	of	patients	from	sites	with	MACE	
follow-up	vs.	patients	from	sites	without	MACE	follow-up	in	the	derivation	cohort	
	
Derivation	Cohort	 Patients	from	sites	with	no	
MACE	follow-up	
N=7,397	
Patients	from	sites	with	
MACE	follow-up	
N=13,735	
P-value	
Age	–	years		 59.2±10.5	 58.2±9.5	 <0.001	
BMI	–	kg/m2	 27.5±5.3*	 27.3±5.1	 0.01	
Female	Gender	 3,429	(46)	 6,285	(46)%	 0.41	
HTN	 3,912	(53)	 6,669	(49)%	 <0.001	
Dyslipidemia	 4,120	(56)	 7,753	(57)%	 0.06	
DM	 1,359	(18)	 1,871	(14)%	 <0.001	
Smoking	 1,490	(20)	 2,181	(16)%	 <0.001	
Chest	pain	typicality†	 	 	 <0.001	
Typical	 1,421	(25)	 1,334	(10)	 <0.001	
Atypical	 1,749	(31)	 5,523	(43)	 <0.001	
Non-Cardiac	 1,011	(18)	 1,086	(8)	 <0.001	
Asymptomatic	 1,438	(26)	 4,979	(39)	 <0.001	
*	BMI	available	in	3,365/7,397	and	13,356/13,735	patients.		
†Chest	pain	typicality	available	in	5,619/7,397	and	12,922/13/735	patients.	 	
	
	
Supplementary	Table	3:	All	cause	death	according	to	SIS%	value	in	the	derivation	cohort	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 	
	 HR	(95%	CI)	 p-value	
All	(n=21,018)	 	 	
				≤50th	percentile	SIS%	 Reference	 –	
				51-75th	percentile	SIS%	 1.7	(1.3-2.3)	 <0.001	
>75th	percentile	SIS%	 2.6	(2.0-3.5)	 <0.001	
	 	 	
Males	(n=11,361)	 	 	
				≤50th	percentile	SIS%	 Reference	 –	
				51-75th	percentile	SIS%	 1.4	(1.0-2.0)	 0.07	
>75th	percentile	SIS%	 2.0	(1.4-2.9)	 <0.001	
	 	 	
Females	(n=9,657)	 	 	
				≤50th	percentile	SIS%	 Reference	 –	
				51-75th	percentile	SIS%	 2.3	(1.5-3.7)	 <0.001	
>75th	percentile	SIS%	 3.8	(2.5-5.8)	 <0.001	
Supplementary	Table	4:	Baseline	characteristics	of	the	validation	cohort	stratified	by	SIS%	groups	
	
	
	
	
	
	
	 All	
	
N=3,030*	
≤50th	
percentile	
N=1576	
51-75th	
percentile	
N=965		
>75th	
percentile	
N=489	
p-value†	
Demographics	 	 	 	 	 	
Age	range	–	yrs	 61±9	 62±9	 59±10	 59±10	 <0.001	
Female	sex	–	no.	(%)	 1,338	(44)	 608	(39)	 495	(51)	 235	(48)	 <0.001	
Body-mass	index	 27.3±5.1	 27.1±5.0	 27.3±5.3	 27.6±4.9	 NS	
	 	 	 	 	 	
Cardiovascular	risk	factors	 	 	 	 	 	
Diabetes	 1,079	(36)	 595	(38)	 303	(32)	 181	(37)	 0.17	
Hypertension	 1,859	(62)	 947	(60)	 561	(59)	 351	(73)	 <0.001	
Dyslipidaemia	 1,367	(46)	 644	(41)	 459	(48)	 264	(54)	 <0.001	
Current	smoker		 552	(20)	 221	(15)	 198	(22)	 133	(29)	 <0.001	
	 	 	 	 	 	
Chest	pain	typicality		 	 	 	 	 	
Typical	angina	 734	(25)	 343	(22)	 257	(27)	 134	(28)	 0.001	
Atypical	angina	 746	(25)	 428	(28)	 222	(24)	 96	(20)	 <0.001	
Non-cardiac	 503	(17)	 238	(15)	 171	(18)	 94	(20)	 0.01	
Asymptomatic	 985	(33)	 540	(35)	 293	(31)	 152	(32)	 NS	
	 	 	 	 Overall		 0.10	
Framingham	risk	score	 	 	 	 	 	
Risk	score	–	mean	±	SD	 15.4±10.2	 16.0±10.3	 14.2±9.9	 16.2±10.0	 0.26	
Risk	category	–	no.	(%)	 	 	 	 	
				<10%		 1,005	(36)	 479	(33)	 374	(41)	 152	(33)	 0.33	
				10-20%	 1,091	(39)	 567	(40)	 344	(38)	 180	(39)	 NS	
				>20%	 716	(25)	 387	(27)	 195	(21)	 134	(29)	 0.69	
	 	 	 Overall	 0.43	
Coronary	artery	disease	 	 	 	 	 	
Normal	 1,076	(36)	 913	(58)	 163	(17)	 0	(0)	 <0.001	
Non-obstructive	 836	(28)	 337	(21)	 368	(38)	 131	(27)	 <0.001	
Obstructive	(≥50%)	 1,118	(37)	 326	(21)	 434	(45)	 358	(73)	 <0.001	
	 	 	 	 Overall		 <0.001	
*BMI	(n=2,450);	FRS	(n=2,812);	diabetes	(n=3,011);	hypertension	(n=3,008);	dyslipidemia	(n=3,005);	smoking	
(n=2,813);	chest	pain	typicality	(n=2,968);	otherwise	complete.	
†p-value	for	chi-square	test	for	trend	or	Cuzik’s	test	for	trend.	NS,	not	significant	ANOVA	or	chi	square	test.	
Supplementary	Figures		
	
	
	
	
	
Supplementary	Figure	1:	Number	of	patients	at	each	year	of	life	(40-79yrs)	in	the	nomogram	
derivation	cohort.	
	
	 	
	Supplementary	Figure	2:	Fitting	of	second-order	polynomial	curves	(solid	lines)	to	raw	SIS	
percentiles	at	each	year	of	life	(joined	by	splines	for	demonstration,	dotted	lines)	is	shown	
for	men	(A)	and	women	(B).	For	the	final	nomographic	representation	presented	in	the	
manuscript,	the	components	of	the	curve	that	spill	back	to	the	left	in	the	lower	percentiles	
have	been	removed.		
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B. Second-order polynomial curves fit to age-SIS percentiles for women
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A. Second-order polynomial curves fit to age-SIS percentiles for men
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